RSNN Annual Report 2018 - Public Summary
2018 has been a year of expansion and consolidation for the RSNN. The number of RSNN members and partner organization has grown, as well as the number of participants in RSNN events. Furthermore, the RSNN has professionalized its communications by launching a new website and setting up an electronic newsletter.
Transition
On June 26, 2018, the RSNN Consortium agreement was signed, which formalized the transition of the RSNN into a new organizational structure. A new governance structure and funding model were put in place that ensure a balance between the different stakeholder groups that are currently part of the RSNN (academia, industry and governmental bodies).
These stakeholder groups are represented in the Steering Committee. An Advisory Board is also in place, which was consulted multiple times during the year. Several members of the Advisory Board were also involved in the program committees for RSNN events.
Growth
The RSNN has grown with 30% in 2018, from 173 to 225members. In addition, partner organisations were added to the network. Since January 1st, 2019, the UMC Groningen has joined the RSNN as a partner. During 2018, HollandBIO was also added as a partner.
The growth of the network is also reflected in the attendance of RSNN events. On June 20th, 2018, 76 participants joined the RSNN Workshop ‘What’s in, what’s out, what’s relevant? – Towards a sensible label’. A scientific paper on the outcome of this workshop has been approved for publication in the British Journal of Clinical Pharmacology.
During the FIGON DMD, on October 1st, 2018, the RSNN organized two sessions around novel cancer treatments and the associated regulatory challenges. A total of 109 RSNN members joined these sessions.
Communication
During the FIGON DMD, the RSNN launched its new website (www.rsnn.nl). This website provides an overview of RSNN events and workshops, as well as news about publications and outcomes of RSNN events.
News on the RSNN website is shared with the network through an electronic newsletter. Three editions were distributed during 2018, of which the 3rd edition was released in a new user-friendly digital format to be used for future newsletters as well.
Looking ahead
In 2019, the RSNN will organize a workshop titled ‘The future of clinical trials and evidence generation, and their use in regulatory decision making’. Two expert meetings are also planned, to which several experts in the field of regulatory science from different stakeholders will be invited in order to determine which knowledge gaps exist on specific topics. Topics for 2019’s expert meetings are pharmaceutical compounding and the regulatory-HTA interface.
In 2019, the RSNN aims to connect with RSNN members to gain more insight in the expertise that is present within the network, and to organize additional RSNN events to help identify knowledge gaps in the field of regulatory science. Furthermore, RSNN will reach out to patient organizations, to better include the patient perspective in discussions on regulatory science.